

#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Bajorin 1



| Section 1. Identif                             | fying Information   |  |                                |  |                  |
|--|---|--|--------------------------------|--|------------------|
| 1. Given Name (First Name)<br>Dean             | 2. Surna<br>Bajorin   | me (Last Name)                                   |                                | 3. Date<br>05-December-2   | 2016             |
| 4. Are you the correspondin                    | g author? Yes   | ✓ No   | Corresponding<br>Joaquim Belln |  |                  |
| 5. Manuscript Title<br>Pembrolizumab as Second | 5. Manuscript Title<br>Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma |  |                                |  |                  |
| 6. Manuscript Identifying Nu<br>16-13683       | . Manuscript Identifying Number (if you know it)<br>6-13683                                   |  |                                |  |                  |
|  |   |  |                                |  |                  |
| Section 2. The Wo                              | ork Under Considera   | tion for Publi                                   | cation                         |  |                  |
|  | work (including but not lin   |  |                                | ernment, commercial, private<br>ird, study design, manuscript p                                |                  |
| Section 3. Releva                              | nt financial activities   | s outside the                                    | submitted wor                  | k.   |                  |
| of compensation) with en                       | tities as described in the four should report relation of interest?                           | e instructions. Uponships that we Yes  \text{No} | se one line for ea             | inancial relationships (rega<br>ch entity; add as many line<br><b>g the 36 months prior to</b> | s as you need by |
| Name of Entity                                 | Grant?  | Personal No                                      | n-Financial<br>Support?        | ner? Comments  |                  |
| Merck  |   | <b>✓</b>   | <b>√</b>                       | Honoraria for speaking,  | travel           |
|  |   |  |                                |  |                  |
| Section 4. Intelled                            | ctual Property Pate   | ents & Copyri                                    | ghts                           |  |                  |
| Do you have any patents,                       | whether planned, pend   | ing or issued, b                                 | roadly relevant to             | o the work? Yes  | No               |

Bajorin 2



| Section 5.       |   |  |  |  |  |
|------------------|---|--|--|--|--|
| Section 5.       | Relationships not covered above   |  |  |  |  |
|                  | Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?               |  |  |  |  |
| Yes, the follo   | wing relationships/conditions/circumstances are present (explain below):  |  |  |  |  |
| ✓ No other rela  | tionships/conditions/circumstances that present a potential conflict of interest  |  |  |  |  |
|                  | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>rnals may ask authors to disclose further information about reported relationships. |  |  |  |  |
|                  |   |  |  |  |  |
| Section 6.       | Disclosure Statement  |  |  |  |  |
| Based on the abo | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box   |  |  |  |  |
| Dr. Bajorin repo | rts personal fees and non-financial support from Merck outside the submitted work.  |  |  |  |  |

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Bajorin 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not **Royalties:** Funds are coming in to you or your institution due to your

patent

Bellmunt 1



| Section 1. Identifying In                              | formation   |  |
|--|---|--|
| 1. Given Name (First Name)<br>Joaquim                  | 2. Surname (Last Name)<br>Bellmunt  | 3. Date<br>28-November-2016  |
| 4. Are you the corresponding author?                   | ✓ Yes No  |  |
| 5. Manuscript Title<br>Pembrolizumab as Second-Line Th | nerapy for Advanced Urothelial Carcinoma  |  |
| 6. Manuscript Identifying Number (if y 16-13683        | you know it)  |  |
|  |   |  |
| Section 2. The Work Und                                | er Consideration for Publication  |  |
|  | uding but not limited to grants, data monitorin   | r (government, commercial, private foundation, etc.) for<br>ng board, study design, manuscript preparation,                                    |
| Section 3. Relevant finar                              | ncial activities outside the submitted  | work.  |
| of compensation) with entities as o                    | described in the instructions. Use one line full report relationships that were <b>present</b> of | ave financial relationships (regardless of amount for each entity; add as many lines as you need by during the 36 months prior to publication. |
| If yes, please fill out the appropriat                 |   |  |
| Name of Entity   | Grant? Personal Non-Financial Support?  | Other? Comments  |
| Merck  |   | Advisory board consultancy   |
| Genentech  |   | Advisory board consultancy   |
|  |   |  |
| Section 4. Intellectual Pr                             | operty Patents & Copyrights   |  |
| Do you have any patents, whether                       | planned, pending or issued, broadly relev   | ant to the work? ☐ Yes 📝 No  |

Bellmunt 2



| Section 5. Relationships not severed above   |
|--|
| Relationships not covered above  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  |
| Yes, the following relationships/conditions/circumstances are present (explain below):   |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6  |
| Section 6. Disclosure Statement  |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.  |
| Dr. Bellmunt reports personal fees from Merck and Genentech outside the submitted work.  |

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Bellmunt 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Choueiri 1



| Section 1. Identifying Inform   | ation  |                         |   |
|---|--|-------------------------|---|
| 1. Given Name (First Name)<br>Toni  | 2. Surname (Last Name)<br>Choueiri                               |                         | 3. Date<br>16-November-2016             |
| 4. Are you the corresponding author?  | ☐ Yes ✓ No   | Corresponding Author    | or's Name                               |
| 5. Manuscript Title<br>Pembrolizumab as Second-Line Therapy   | r for Advanced Urothelial  | Carcinoma               |   |
| 6. Manuscript Identifying Number (if you kno  | ow it)   | _                       |   |
|   |  |                         |   |
| Section 2. The Work Under Co  | onsideration for Public  | ation                   |   |
| Did you or your institution <b>at any time</b> received any aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of intereal lf yes, please fill out the appropriate info   | but not limited to grants, da                                    | ta monitoring board, st | udy design, manuscript preparation,     |
| Excess rows can be removed by pressing  |  | e more than one ent     | button to add a row.                    |
| Name of Institution/Company   | Grant  | n-Financial Other?      | Comments                                |
| Merck   | <b>✓</b>   |                         | Trial support                           |
| Pfizer  | <b>✓</b>   |                         | Trial support                           |
| Section 3. Polovant financial c   |  |                         |   |
| Relevant financial a  | activities outside the s   | ubmitted work.          |   |
| Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should repare there any relevant conflicts of interesting the second conflicts of interesting | bed in the instructions. Us<br>ort relationships that wer<br>st? | e one line for each e   | ntity; add as many lines as you need by |
| Name of Entity  | Grant  | n-Financial other?      | Comments                                |
| Merck   |  |                         | Advisory board                          |

Choueiri 2



| Section 4. Intellectual Property Patents & Copyrights   |  |  |  |  |
|---|--|--|--|--|
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume   |  |  |  |  |
| Section 5. Relationships not covered above  |  |  |  |  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?   |  |  |  |  |
| Yes, the following relationships/conditions/circumstances are present (explain below):  |  |  |  |  |
| No other relationships/conditions/circumstances that present a potential conflict of interest   |  |  |  |  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. |  |  |  |  |
| Section 6. Disclosure Statement   |  |  |  |  |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.   |  |  |  |  |
| Dr. Choueiri reports grant and other support from Merck and Pfizer during the conduct of the study, and personal fees from Merck outside the submitted work.  |  |  |  |  |

#### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Choueiri 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Climent 1



| Section 1. Identifying Inform   | ation   |  |  |
|---|---|--|--|
| 1. Given Name (First Name)<br>Miguel Angel  | 2. Surname (Last Name)<br>Climent   | 3. Date<br>29-November-2016  |  |
| 4. Are you the corresponding author?  | Yes ✓ No  | Corresponding Author's Name<br>Joaquim Bellmunt  |  |
| 5. Manuscript Title<br>Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma   |   |  |  |
| 6. Manuscript Identifying Number (if you kn<br>16-13683   | ow it)  | _  |  |
| Section 2. The Work Under Co  |   |  |  |
| The Work Under Co   | nsideration for Public  | ation  |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No |   |  |  |
| Section 3. Relevant financial   | activities outside the s  | submitted work.  |  |
| Place a check in the appropriate boxes in of compensation) with entities as descri  | n the table to indicate who<br>bed in the instructions. Us<br>ort relationships that wer<br>st? | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by se present during the 36 months prior to publication. |  |
| Name of Entity  | Grant? Personal Nor   | n-Financial other? Comments  |  |
| Roche   |   | Advisory board   |  |
| Pierre Fabre  |   | Advisory board   |  |
| Bristol-Myers Squibb  |   | Advisory board   |  |
| Section 4. Intellectual Proper  | ty Patents & Copyrig  | phts   |  |
| Do you have any patents, whether plann  | ned, pending or issued, br  | oadly relevant to the work? Yes V No   |  |

Climent 2



| Section 5.       |   |  |  |  |  |
|------------------|---|--|--|--|--|
| Section 5.       | Relationships not covered above   |  |  |  |  |
|                  | Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?               |  |  |  |  |
| Yes, the follo   | wing relationships/conditions/circumstances are present (explain below):  |  |  |  |  |
| ✓ No other rela  | tionships/conditions/circumstances that present a potential conflict of interest  |  |  |  |  |
|                  | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>rnals may ask authors to disclose further information about reported relationships. |  |  |  |  |
| Section 6.       | Disclosure Statement  |  |  |  |  |
| _                | Disclosure Statement  |  |  |  |  |
| Based on the abo | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box   |  |  |  |  |
| Dr. Climent repo | orts personal fees from Roche, Pierre Fabre, and Bristol-Myers Squibb outside the submitted work.   |  |  |  |  |

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Climent 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Culine 1



| Section 1.  | Identifying Inform                         | ation  |   |            |
|---|--|--|---|------------|
| 1. Given Name (Fir<br>Stéphane  | st Name)                                   | 2. Surname (Last Name)<br>Culine                           | 3. Date<br>28-November-2016   |            |
| 4. Are you the corr   |  |  | Corresponding Author's Name<br>Joaquim Bellmunt   |            |
| 5. Manuscript Title<br>Pembrolizumab  |  | y for Advanced Urothelial                                  | Carcinoma   |            |
| 6. Manuscript Iden<br>16-13683  | ntifying Number (if you kn                 | ow it)   |   |            |
|   |  |  |   |            |
| Section 2.  | The Work Under Co                          | onsideration for Public                                    | ation   |            |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  Volume |  |  |   |            |
| Section 3.  | Relevant financial                         | activities outside the s                                   | ubmitted work.  |            |
| of compensation clicking the "Add   | ) with entities as descri                  | bed in the instructions. Us<br>port relationships that wer | ether you have financial relationships (regardless<br>e one line for each entity; add as many lines as yo<br>e <b>present during the 36 months prior to publi</b> | ou need by |
| Section 4.  | locally stood Door                         | to Determine Commit  | lh to   |            |
|   | Intellectual Property Patents & Copyrights |  |   |            |
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo   |  |  |   |            |

Culine 2



| Section 5. Relationships not sovered above   |
|--|
| Relationships not covered above  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  |
| Yes, the following relationships/conditions/circumstances are present (explain below):   |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement  |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.  |
| Dr. Culine has nothing to disclose.  |

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Culine 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

de Wit



| Section 1.  | Identifying Inform   | mation   |   |
|---|--|--|---|
| 1. Given Name (Fi   | irst Name)   | 2. Surname (Last Na<br>de Wit                                | 3. Date<br>31-October-2016  |
| 4. Are you the co   | responding author?   | ☐ Yes ✓ No   | Corresponding Author's Name Joaquim Bellmunt  |
| 5. Manuscript Titl<br>Pembrolizumab   | e<br>as Second-Line Thera                                      | py for Advanced Urot   | helial Carcinoma  |
| 6. Manuscript Ide<br>16-13683   | ntifying Number (if you k                                      | know it)   |   |
|   | •  |  |   |
| Section 2.  | The Work Under (   | Consideration for F  | Publication   |
| any aspect of the s<br>statistical analysis,<br>Are there any re<br>If yes, please fill | submitted work (includin<br>etc.)?<br>levant conflicts of inte | ng but not limited to gradues.  Yes  formation below. If you | es from a third party (government, commercial, private foundation, etc.) for ints, data monitoring board, study design, manuscript preparation,  No ou have more than one entity press the "ADD" button to add a row. |
| Name of Institut  | tion/Company   | Grant? Personal Fees?  | Non-Financial Support? Comments   |
| Merck   |  |  | Steering committee  |
|   |  |  |   |
| Section 3.  | Relevant financia  | l activities outside   | the submitted work.   |
| of compensation<br>clicking the "Add<br>Are there any re                                | n) with entities as desc                                       | ribed in the instruction report relationships the rest?  Yes | te whether you have financial relationships (regardless of amount ons. Use one line for each entity; add as many lines as you need by at were <b>present during the 36 months prior to publication</b> .  No          |
| Name of Entity  |  | Grant? Personal Fees?  | Non-Financial Support? Comments   |
| Eli Lilly   |  |  | Advisory  |

de Wit



| Section 4. Intellectual Property Patents & Copyrights  |
|--|
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume  |
| Section 5. Relationships not covered above   |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  |
| Yes, the following relationships/conditions/circumstances are present (explain below):   |
| No other relationships/conditions/circumstances that present a potential conflict of interest  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement  |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.  |
| Dr. de Wit reports personal fees from Merck during the conduct of the study, and personal fees from Eli Lilly outside the submitted work.  |

#### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

de Wit



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



| Section 1. Identifying Inforn   | nation                         |                         |  |
|---|--------------------------------|-------------------------|--|
| Given Name (First Name)  Lawrence   | 2. Surname (Last Name)<br>Fong |                         | 3. Date<br>17-November-2016            |
| 4. Are you the corresponding author?  | ☐ Yes ✓ No                     | Corresponding Author    | r's Name                               |
| 5. Manuscript Title<br>Pembrolizumab as Second-Line Therap  | by for Advanced Urothelial     | Carcinoma               |  |
| 6. Manuscript Identifying Number (if you king 16-13683  | now it)                        | _                       |  |
|   |                                |                         |  |
| Section 2. The Work Under C   | onsideration for Publi         | cation                  |  |
| Did you or your institution <b>at any time</b> receany aspect of the submitted work (including statistical analysis, etc.)? |                                |                         |  |
| Are there any relevant conflicts of inter-  |                                |                         |  |
| If yes, please fill out the appropriate info<br>Excess rows can be removed by pressin                                       |                                | ve more than one entit  | y press the "ADD" button to add a row. |
| Name of Institution/Company   | Grant                          | n-Financial Other?      | Comments                               |
| Merck   | <b>✓</b>                       |                         |  |
|   |                                |                         |  |
| Section 3. Polovant financial   | activities outside the         | cubmitted work          |  |
| Place a check in the appropriate boxes  | in the table to indicate wh    | nether you have financi |  |
| of compensation) with entities as descr<br>clicking the "Add +" box. You should re  |                                |                         |  |
| Are there any relevant conflicts of inter-  | est? ✓ Yes No                  |                         |  |
| If yes, please fill out the appropriate info  | ormation below.                |                         |  |
| Name of Entity  | Grant                          | n-Financial Other?      | Comments                               |
| Dendreon  | <b>✓</b>                       |                         |  |
| Bristol-Myers Squibb  | <b>✓</b>                       |                         |  |
| Roche/Genentech   | <b>✓</b>                       |                         |  |



| Name of Entity   | Grant?      | Personal<br>Fees?      | Non-Financial Support? | Other?     | Comments                           |  |
|--|-------------|------------------------|------------------------|------------|------------------------------------|--|
| AbbVie   | <b>✓</b>    |                        |                        |            |                                    |  |
| Amgen  | <b>✓</b>    |                        |                        |            |                                    |  |
| Section 4  |             |                        |                        |            |                                    |  |
| Section 4. Intellectual Propert  | y Pate      | ents & Co <sub>l</sub> | pyrights               |            |                                    |  |
| Do you have any patents, whether plann   | ed, pend    | ing or issue           | ed, broadly releva     | nt to the  | work? Yes 🗸 No                     |  |
| Section 5. Relationships not c   | overed      | above                  |                        |            |                                    |  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  Yes, the following relationships/conditions/circumstances are present (explain below):  No other relationships/conditions/circumstances that present a potential conflict of interest |             |                        |                        |            |                                    |  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.  |             |                        |                        |            |                                    |  |
| Section 6. Disclosure Statemen   | nt          |                        |                        |            |                                    |  |
| Based on the above disclosures, this form below.   | n will auto | omatically (           | generate a disclos     | sure state | ment, which will appear in the box |  |
| Dr. Fong reports grant support from Merck during the conduct of the study; and grant support from Dendreon, Bristol-Myers Squibb, Roche/Genentech, AbbVie, and Amgen outside the submitted work.   |             |                        |                        |            |                                    |  |



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Fradet 1



**Identifying Information** 

Section 1.

1. Given Name (First Name)

# **ICMJE Form for Disclosure of Potential Conflicts of Interest**

2. Surname (Last Name)

3. Date

| Yves   | Fradet  |  |                         |           | 28-November-2016                     |         |
|--|---|--|-------------------------|-----------|--------------------------------------|---------|
| 4. Are you the corresponding author?   | Yes   | <b>✓</b> No  | Correspond<br>Joaquim B | •         | or's Name                            |         |
| 5. Manuscript Title<br>Pembrolizumab as Second-Line Thera  | apy for Adva  | nced Urothe  | elial Carcinoma         |           |                                      |         |
| 6. Manuscript Identifying Number (if you 16-13683  | know it)  |  |                         |           |                                      |         |
| Section 2  |   |  |                         |           |                                      |         |
| Section 2. The Work Under  | Considera   | tion for Pu  | blication               |           |                                      |         |
| Did you or your institution <b>at any time</b> re any aspect of the submitted work (includi statistical analysis, etc.)?  Are there any relevant conflicts of inte                                     | ng but not lin  |  | s, data monitoring      |           |                                      | C.) 101 |
| Section 3. Relevant financia   | al activities   | outside tl   | ne submitted            | work.     |                                      |         |
| Place a check in the appropriate boxe of compensation) with entities as desclicking the "Add +" box. You should a Are there any relevant conflicts of intelligence, please fill out the appropriate in | cribed in the report relation of the contract | instructions<br>onships that<br>Yes \(\Boxed{\text{N}}\) | s. Use one line fo      | r each er | ntity; add as many lines as you need |         |
| Name of Entity   | Grant?  | Personal<br>Fees?  | Non-Financial Support?  | Other?    | Comments                             |         |
| stellas  | <b>✓</b>  | <b>✓</b>   |                         |           | Consultant                           |         |
|  |   | <b>✓</b>   |                         |           | Companie                             |         |
| ayer   |   |  |                         |           | Consultant                           |         |
| •  |   | <b>✓</b>   |                         |           | Consultant                           |         |
| mgen   |   |  |                         |           |                                      |         |
| mgen<br>Merck  |   | <b>V</b>   |                         |           | Consultant                           |         |
| ayer mgen  Merck oche anofi  |   | ✓<br>✓   |                         |           | Consultant Consultant                |         |

Fradet 2



| Section 4. Intellectual Property Patents & Copyrights  |
|--|
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo  |
| Section 5. Relationships not covered above   |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  |
| Yes, the following relationships/conditions/circumstances are present (explain below):   |
| No other relationships/conditions/circumstances that present a potential conflict of interest  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement  |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.  |
| Dr. Fradet reports grant support and personal fees from Astellas, Amgen, and AstraZeneca, and personal fees from Merck, Roche, Sanofi, and Bayer outside the submitted work.   |

#### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Fradet 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Gerritsen 1



| Section 1. Identifying Inform   | nation                              |                               |   |   |  |  |
|---|-------------------------------------|-------------------------------|---|---|--|--|
| 1. Given Name (First Name)<br>Winald  | 2. Surname (Last Name)<br>Gerritsen |                               | 3. Date<br>14-November-2016   |   |  |  |
| 4. Are you the corresponding author?  | Yes Vo                              | Corresponding<br>Joaquim Bell | g Author's Name<br>munt   |   |  |  |
| 5. Manuscript Title<br>Pembrolizumab as Second-Line Therap  | y for Advanced Urothelia            | al Carcinoma                  |   |   |  |  |
| 6. Manuscript Identifying Number (if you kr<br>16-13684   | now it)                             |                               |   |   |  |  |
|   |                                     | _                             |   |   |  |  |
| Section 2. The Work Under C   | onsideration for Publ               | lication                      |   |   |  |  |
| Did you or your institution <b>at any time</b> receany aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of interesting the statistical analysis.  | g but not limited to grants, o      |                               | vernment, commercial, private foundation, etc.) fo<br>oard, study design, manuscript preparation, | r |  |  |
| Section 3. Relevant financial   | activities outside the              | submitted wo                  | ork.  |   |  |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes No  If yes, please fill out the appropriate information below. |                                     |                               |   |   |  |  |
| Name of Entity  | Grant? Personal No                  | on-Financial O                | ther? Comments  |   |  |  |
| Amgen   |                                     |                               | Advisory board  |   |  |  |
| Astellas  | <b>✓</b>                            |                               | Advisory board, research funding  |   |  |  |
| Bristol-Myers Squibb  |                                     |                               | Speakers fee  |   |  |  |
| Janssen-Cilag   | <b>/</b>                            |                               | Advisory board, research funding, speakers fee  |   |  |  |
| Curevac   |                                     |                               | Advisory board  |   |  |  |
| Merck Sharp & Dohme   |                                     |                               | Advisory board  |   |  |  |
| Bayer   |                                     |                               | Speakers fee, advisory board  |   |  |  |

Gerritsen 2



| Section 4. Intellectual Property Patents & Copyrights   |
|---|
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes V  |
| Section 5. Relationships not covered above  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?   |
| Yes, the following relationships/conditions/circumstances are present (explain below):  |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest   |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement   |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.   |
| Dr. Gerritsen reports grant support and personal fees from Astellas and Janssen-Cilag, and personal fees from Amgen, Bristol-Myers Squibb, Curevac, Merck Sharp & Dohme, and Bayer outside the submitted work.                        |

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Gerritsen 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Gurney 1



| Section 1. Identifying Inform   | ation  |                                |                               |         |
|---|--|--------------------------------|-------------------------------|---------|
| Given Name (First Name)  Howard   | 2. Surname (Last Name)<br>Gurney                               |                                | 3. Date<br>18-November-2016   |         |
| 4. Are you the corresponding author?  | Yes ✓ No   | Corresponding Author's Nai     | me                            |         |
| 5. Manuscript Title<br>Pembrolizumab as Second-Line Therap  | y for Advanced Urothelial                                      | Carcinoma                      |                               |         |
| 6. Manuscript Identifying Number (if you kn<br>16-13683   | ow it)   | _                              |                               |         |
| Cartinus  |  |                                |                               |         |
| Section 2. The Work Under Co  | onsideration for Public  | cation                         |                               |         |
| Did you or your institution <b>at any time</b> recei<br>any aspect of the submitted work (including<br>statistical analysis, etc.)?<br>Are there any relevant conflicts of intere   | but not limited to grants, da                                  |                                |                               | :.) for |
| Section 3. Polyvent financial   |  |                                |                               |         |
| Relevant financial  | activities outside the s                                       | submitted work.                |                               |         |
| Place a check in the appropriate boxes i<br>of compensation) with entities as descri<br>clicking the "Add +" box. You should rep<br>Are there any relevant conflicts of interes<br>If yes, please fill out the appropriate info | bed in the instructions. Us<br>port relationships that werest? | se one line for each entity; a | add as many lines as you need |         |
| Name of Entity  | Grant? Personal Noi  | n-Financial Other? Con         | nments                        |         |
| Pfizer  | <b>✓</b>   |                                |                               |         |
| Bristol-Myers Squibb  |  | Advise                         | ory board                     |         |
| Astellas  |  | Advise                         | ory board                     |         |
| Roche   |  | Adviso                         | ory board                     |         |

Gurney 2



| Section 4. Intellectual Property Patents & Copyrights   |
|---|
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume   |
| Section 5. Relationships not covered above  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?   |
| Yes, the following relationships/conditions/circumstances are present (explain below):  |
| No other relationships/conditions/circumstances that present a potential conflict of interest   |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement   |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.   |
| Dr. Gurney reports grant support from Pfizer, and personal fees from Bristol-Myers Squibb, Astellas, and Roche outside the submitted work.  |

#### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Gurney 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Lee 1



|   | Section 1. Identifying Information  | ation   |   |                                      |         |  |  |
|---|---|---|---|--------------------------------------|---------|--|--|
|   | 1. Given Name (First Name)<br>Jae Lyun  | 2. Surname (Last Name)<br>Lee   |   | 3. Date<br>17-November-2016          |         |  |  |
|   | 4. Are you the corresponding author?  | Yes ✓ No  | Corresponding Autho                                     | or's Name                            |         |  |  |
|   | 5. Manuscript Title<br>Pembrolizumab as Second-Line Therapy   |   |   |                                      |         |  |  |
|   | 6. Manuscript Identifying Number (if you kno<br>16-13683  | ow it)  | _   |                                      |         |  |  |
|   |   |   |   |                                      |         |  |  |
|   | Section 2. The Work Under Co  | nsideration for Publi   | cation  |                                      |         |  |  |
|   | Did you or your institution <b>at any time</b> received any aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of interests   | but not limited to grants, da   |   |                                      | c.) for |  |  |
|   | Continu 2   |   |   |                                      |         |  |  |
|   | Section 3. Relevant financial a   | activities outside the  | submitted work.   |                                      |         |  |  |
|   | Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should report there any relevant conflicts of interest lf yes, please fill out the appropriate information. | bed in the instructions. Use ort relations has we st?   Yes   No rmation below. | se one line for each en<br>re <b>present during the</b> | itity; add as many lines as you need | d by    |  |  |
|   | Name of Entity  | Grant? Personal No  | n-Financial Support?                                    | Comments                             |         |  |  |
| Α | sstraZeneca   |   |   | Advisory boards                      |         |  |  |
| Α | stellas   |   |   | Advisory boards                      |         |  |  |
| Ε | isai  |   |   | Advisory boards                      |         |  |  |
| P | fizer   |   |   | Advisory boards                      |         |  |  |

Lee 2



| Soutien A   |
|---|
| Section 4. Intellectual Property Patents & Copyrights   |
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo   |
| Section 5. Relationships not covered above  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?   |
| Yes, the following relationships/conditions/circumstances are present (explain below):  |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest   |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement   |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.   |
| Dr. Lee reports personal fees from AstraZeneca, Astellas, Eisai, and Pfizer outside the submitted work.   |

#### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Lee 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Mai 1



| Section 1. Identifying Inform   | nation                        |   |  |  |  |
|---|-------------------------------|---|--|--|--|
| Given Name (First Name)  Yabing   | 2. Surname (Last Name)<br>Mai | 3. Date<br>06-December-2016                     |  |  |  |
| 4. Are you the corresponding author?  | ☐ Yes ✓ No                    | Corresponding Author's Name<br>Joaquim Bellmunt |  |  |  |
| 5. Manuscript Title<br>Pembrolizumab as Second-Line Therap  | by for Advanced Urothelial    | Carcinoma                                       |  |  |  |
| 6. Manuscript Identifying Number (if you ki   | now it)                       | _   |  |  |  |
| Section 2. The Work Under C   | onsideration for Publi        | cation  |  |  |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No   |                               |   |  |  |  |
| Section 3. Relevant financial   | activities outside the        | submitted work.                                 |  |  |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes No  If yes, please fill out the appropriate information below. |                               |   |  |  |  |
| Name of Entity  | Grant? Personal No            | on-Financial Other? Comments                    |  |  |  |
| Merck   |                               | Employment, Stock options                       |  |  |  |
|   |                               |   |  |  |  |
| Section 4. Intellectual Prope   | rty Patents & Copyri          | ghts  |  |  |  |
| Do you have any patents, whether plan   | ned, pending or issued, b     | roadly relevant to the work? Yes V No           |  |  |  |

Mai 2



| Section 5. Relationships not severed above   |
|--|
| Relationships not covered above  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  |
| Yes, the following relationships/conditions/circumstances are present (explain below):   |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement  |
| Disclosure Statement   |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.  |
| Dr. Mai reports personal fees and other support from Merck outside the submitted work.   |

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Mai 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



| Section 1. Identifying Inform   | nation   |   |  |         |  |
|---|--|---|--|---------|--|
| identifying inform  | iation   |   |  |         |  |
| 1. Given Name (First Name)<br>Andrea  | 2. Surname (Last Nar<br>Necchi                 | ne)   | 3. Date<br>27-October-2016                         |         |  |
| 4. Are you the corresponding author?  | Yes 🗸 No                                       | •   | Corresponding Author's Name<br>Joaquim Bellmunt    |         |  |
| 5. Manuscript Title<br>Pembrolizumab as Second-Line Therap  | y for Advanced Uroth                           | nelial Carcinoma                                |  |         |  |
| 6. Manuscript Identifying Number (if you kr<br>16-13683   | now it)  |   |  |         |  |
|   |  |   |  |         |  |
| Section 2. The Work Under Co  | onsideration for P                             | ublication                                      |  |         |  |
| Did you or your institution <b>at any time</b> rece<br>any aspect of the submitted work (including<br>statistical analysis, etc.)?<br>Are there any relevant conflicts of intere  | but not limited to grar                        | nts, data monitoring                            |  |         |  |
| Section 3. Relevant financial   | activities outside                             | the submitted                                   | work.  |         |  |
| Place a check in the appropriate boxes in of compensation) with entities as describing the "Add +" box. You should repair to the "Add +" box. | ibed in the instruction port relationships tha | ns. Use one line fo<br>It were <b>present d</b> | or each entity; add as many lines as you           | need by |  |
| Are there any relevant conflicts of intered<br>If yes, please fill out the appropriate info   |  | No  |  |         |  |
|   |  |   |  |         |  |
| Name of Entity  | Grant? Personal Fees?                          | Non-Financial Support?                          | Other? Comments                                    |         |  |
| Millennium/Takeda   | <b>✓</b>                                       |   | Grant for investigator-sponsored research          |         |  |
| Amgen   | <b>✓</b>                                       |   | Grant for investigator-sponsored research          |         |  |
| Novartis  | <b>✓</b>                                       |   | Grant for investigator-sponsored research          |         |  |
| Merck Sharp & Dohme   | <b>✓</b>                                       |   | Grant for investigator-sponsored research; Advisor |         |  |
| Roche   | <b>✓</b>                                       |   | Grant for investigator-sponsored research; Advisor |         |  |



| Name of Entity   | Grant?     | Personal<br>Fees? | Non-Financial Support? | Other?     | Comments   |        |
|--|------------|-------------------|------------------------|------------|--|--------|
| AstraZeneca  | <b>✓</b>   | <b>✓</b>          |                        |            | Grant for investigator-sponsored research; Advisor |        |
| Bayer  |            | <b>✓</b>          |                        |            | Advisor  |        |
|  |            |                   |                        |            |  |        |
| Section 4. Intellectual Propert  | ty Pate    | ents & Co         | pyrights               |            |  |        |
| Do you have any patents, whether plann   |            |                   |                        | nt to the  | work? Yes 🗸 No                                     |        |
| Do you have any paterns, whether plans   | ica, peria | 9 01 13540        | ia, broadly releva     |            | workresne  |        |
| Section 5. Relationships not o   | overed     | above             |                        |            |  |        |
| Are there other relationships or activities  |            |                   |                        | nfluence   | d, or that give the appearance of                  |        |
| potentially influencing, what you wrote i  | n the sub  | mitted wo         | rk?                    |            |  |        |
| Yes, the following relationships/cond  |            |                   |                        |            |  |        |
| ✓ No other relationships/conditions/ci   | rcumstan   | ces that pro      | esent a potential (    | conflict o | f interest   |        |
| At the time of manuscript acceptance, jo<br>On occasion, journals may ask authors to |            |                   |                        |            | •  | nents. |
| ,,,  |            |                   |                        | -          |  |        |
| Section 6. Disclosure Stateme  | nt         |                   |                        |            |  |        |
| Based on the above disclosures, this form  |            | omatically (      | generate a disclos     | sure state | ement, which will appear in the box                |        |
| below.   |            |                   |                        |            |  |        |
|  |            |                   |                        |            |  |        |
| Dr. Necchi reports grant support from M Merck Sharp & Dohme, Roche, and Astra        |            |                   |                        |            |  |        |
|  |            |                   |                        |            |  |        |
|  |            |                   |                        |            |  |        |
|  |            |                   |                        |            |  |        |



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Perini 1



| Section 1. Identifying Inform   | nation   |   |
|---|--|---|
| 1. Given Name (First Name)<br>Rodolfo R.  | 2. Surname (Last Name)<br>Perini                                     | 3. Date<br>06-December-2016   |
| 4. Are you the corresponding author?  | ☐ Yes    ✓ No  | Corresponding Author's Name<br>Joaquim Bellmunt   |
| 5. Manuscript Title<br>Pembrolizumab as Second-Line Therap  | by for Advanced Urothelia  | al Carcinoma  |
| 6. Manuscript Identifying Number (if you k<br>16-13683  | now it)  |   |
|   |  |   |
| Section 2. The Work Under C   | onsideration for Publ  | ication   |
|   | g but not limited to grants, c                                       | m a third party (government, commercial, private foundation, etc.) for data monitoring board, study design, manuscript preparation,   |
| Section 3. Relevant financial   | activities outside the   | submitted work.   |
| of compensation) with entities as descr   | ribed in the instructions. Uport relationships that we est?  Yes  No | hether you have financial relationships (regardless of amount Use one line for each entity; add as many lines as you need by ere <b>present during the 36 months prior to publication</b> . |
| Name of Entity  | Grant? Personal No   | on-Financial Other? Comments  |
| Merck   |  | Employment, stock options   |
|   |  |   |
| Section 4. Intellectual Prope   | rty Patents & Copyr  | ights   |
| Do you have any patents, whether plan<br>If yes, please fill out the appropriate inf<br>Excess rows can be removed by pressin | ormation below. If you ha  | proadly relevant to the work?  Yes  No ave more than one entity press the "ADD" button to add a row.  |

Perini 2



| Patent?   | Pending?       | Issued?    | Licensed?     | Royalties?     | Licensee?          | Comments                     |        |
|---|----------------|------------|---------------|----------------|--------------------|------------------------------|--------|
| Combination of a PD-1 antagonist<br>and a listeria-based vaccine for<br>treating prostate cancer (Application<br>US 20160022814 A1) | <b>✓</b>       |            |               |                |                    |                              |        |
| Treating cancer with a combination of a PD-1 antagonist and a VEGFR inhibitor (Patent 15101409)                                     | <b>✓</b>       |            |               |                |                    |                              |        |
| Section 5. Relationshi  | ps not cove    | ered abo   | ove           |                |                    |                              |        |
| Are there other relationships or potentially influencing, what yo   | activities tha | nt readers | could perce   | eive to have   | influenced, or tha | at give the appearance of    |        |
| Yes, the following relationsh  No other relationships/cond  |                |            |               |                |                    | st                           |        |
| At the time of manuscript accep<br>On occasion, journals may ask a  |                |            |               |                |                    |                              | nents. |
| Section 6. Disclosure S   | tatomout       |            |               |                |                    |                              |        |
| Based on the above disclosures, below.  |                | ll automa  | ntically gene | rate a disclo  | sure statement, v  | which will appear in the box |        |
| Dr. Perini reports personal fees pending patents related to the (Application US 20160022814 A (Patent 15101409).                    | combinatior    | of a PD-   | 1 antagonis   | t and a lister | ia-based vaccine   | for treating prostate cancer |        |

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Perini 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



| Section 1.                          | Identifying Inforn                               | nation                    |              |                       |  |  |  |
|-------------------------------------|--|---------------------------|--------------|-----------------------|--|--|--|
| 1. Given Name (Fi<br>Daniel         | irst Name)                                       | 2. Surname (L<br>Petrylak | .ast Name)   |                       |  | 3. Date<br>07-December-2016  |  |
| 4. Are you the co                   | rresponding author?                              | Yes 🗸                     | No           | -                     | Corresponding Author's Name Joaquim Bellmunt |  |  |
| 5. Manuscript Titl<br>Pembrolizumab | e<br>as Second-Line Therap                       | by for Advanced           | d Urothelial | Carcinoma             |  |  |  |
| 6. Manuscript Ide<br>16-13683       | ntifying Number (if you k                        | now it)                   |              | _                     |  |  |  |
|                                     |  |                           |              |                       |  |  |  |
| Section 2.                          | The Work Under C                                 | onsideration              | for Public   | ation                 |  |  |  |
|                                     | submitted work (includin                         |                           |              |                       |  | commercial, private foundation, etc.) for design, manuscript preparation,                                    |  |
| =                                   | levant conflicts of inter                        | est? ✓ Yes                | No           |                       |  |  |  |
|                                     | out the appropriate inf<br>be removed by pressir |                           | •            | e more than           | one entity p                                 | press the "ADD" button to add a row.   |  |
| Name of Institu                     | , ,  | Grant? Per                | sonal Nor    | -Financial<br>upport  | Other?                                       | omments  |  |
| Merck                               |  | <b>√</b>                  |              |                       |  |  |  |
|                                     |  |                           |              |                       |  |  |  |
| Section 3.                          | Relevant financial                               | activities ou             | tside the s  | ubmitted <sup>,</sup> | work.  |  |  |
| of compensation                     | n) with entities as desci                        | ribed in the inst         | ructions. Us | e one line fo         | or each entity                               | relationships (regardless of amount<br>y; add as many lines as you need by<br>5 months prior to publication. |  |
| •                                   | levant conflicts of inter                        |                           | No           |                       |  |  |  |
| If yes, please fill                 | out the appropriate inf                          | ormation below            | V.           |                       |  |  |  |
| Name of Entity                      |  | Grant                     |              | -Financial<br>upport  | Other?                                       | omments  |  |
| Merck                               |  | <b>✓</b>                  |              |                       | Gra  | ant  |  |
| Celgene                             |  | <b>✓</b>                  |              |                       | Gra  | ant  |  |
| Agensys                             |  | <b>✓</b>                  |              |                       | Gra  | ant  |  |



| Name of Entity   | Grant?     | Personal<br>Fees | Non-Financial Support? | Other?   | Comments                                   |  |  |
|--|------------|------------------|------------------------|----------|--|--|--|
| Eli Lilly  | <b>✓</b>   |                  |                        |          | Grant                                      |  |  |
| Millennium Pharmaceuticals   | <b>✓</b>   | <b>✓</b>         |                        |          | Grant, consulting                          |  |  |
| Dendreon Corp.   | <b>✓</b>   | <b>✓</b>         |                        |          | Grant, consulting                          |  |  |
| Sanofi Aventis   | <b>✓</b>   | $\checkmark$     |                        |          | Grant, consulting                          |  |  |
| Roche Laboratories   | <b>✓</b>   | $\checkmark$     |                        |          | Grant, consulting                          |  |  |
| Bayer  |            | $\checkmark$     |                        |          | Consulting                                 |  |  |
| Johnson & Johnson  |            | $\checkmark$     |                        |          | Consulting                                 |  |  |
| Exelixis   |            | $\checkmark$     |                        |          | Consulting                                 |  |  |
| Ferring Pharmaceuticals  |            | $\checkmark$     |                        |          | Consulting                                 |  |  |
| Medivation   |            | $\checkmark$     |                        |          | Consulting                                 |  |  |
| Pfizer   |            | $\checkmark$     |                        |          | Consulting                                 |  |  |
| Bellicum Pharmaceuticals   |            | <b>✓</b>         |                        | <b>✓</b> | Consulting, ownership interest/involvement |  |  |
| Tyme Pharmaceuticals   |            | <b>✓</b>         |                        | <b>✓</b> | Consulting, ownership interest/involvement |  |  |
| Section 4. Intellectual Property Patents & Copyrights  Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No  Section 5. Relationships not covered above |            |                  |                        |          |  |  |  |
| Are there other relationships or activities potentially influencing, what you wrote  Yes, the following relationships/cond   | in the sub | mitted wo        | rk?                    |          |  |  |  |
| ✓ No other relationships/conditions/ci   |            |                  |                        |          |  |  |  |
| At the time of manuscript acceptance, jo<br>On occasion, journals may ask authors to   |            |                  |                        |          | •  |  |  |

#### Section 6.

#### **Disclosure Statement**

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Petrylak reports grant support from Merck during the conduct of the study; grant support from Merck, Celgene, Agensys, and Eli Lilly, grant support and personal fees from Millennium Pharmaceuticals, Dendreon Corp., Sanofi Aventis, and Roche Laboratories, personal fees from Bayer, Johnson & Johnson, Exelixis, Ferring Pharmaceuticals, Medivation, and Pfizer, and personal fees and other support from Bellicum Pharmaceuticals and Tyme Pharmaceuticals outside the submitted work.

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Poehlein 1



| Section 1. Identifying Inforn                                  | nation   |  |
|--|--|--|
|  |  |  |
| <ol> <li>Given Name (First Name)</li> <li>Christian</li> </ol> | <ol><li>Surname (Last Name)</li><li>Poehlein</li></ol> | 3. Date<br>06-December-2016  |
| 4. Are you the corresponding outhor?                           | Vos. / No  | Corresponding Author's Name  |
| 4. Are you the corresponding author?                           | Yes ✓ No   | Corresponding Author's Name  Joaquim Bellmunt  |
| 5. Manuscript Title<br>Pembrolizumab as Second-Line Therap     | by for Advanced Urothelial                             |  |
| 6. Manuscript Identifying Number (if you k                     | now it)  |  |
|  |  |  |
| Section 2. The World Under C                                   |  |  |
| The work onder C   | onsideration for Publi                                 |  |
|  |  | a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,   |
| Are there any relevant conflicts of inter-                     | est? Yes V No  |  |
|  |  |  |
|  |  |  |
| Section 3. Relevant financial                                  | activities outside the                                 | submitted work.  |
| of compensation) with entities as descr                        | ibed in the instructions. U                            | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication. |
| Are there any relevant conflicts of inter                      | · ·  |  |
| If yes, please fill out the appropriate info                   | ormation below.  |  |
| Name of Entity   | Grant? Personal No                                     | n-Financial Other? Comments  |
| Легск & Co., Inc.  |  | Employment, stock options  |
| Bayer Health Care Oncology                                     |  | Past employment, stock options   |
|  |  |  |
|  |  |  |
| Section 4. Intellectual Prope                                  | rty Patents & Copyri                                   | ghts   |
| Do you have any patents, whether plan                          | ined, pending or issued, bi                            | roadly relevant to the work? 🗸 Yes 🔲 No  |
| If yes, please fill out the appropriate inf                    | ormation below. If you hav                             | ve more than one entity press the "ADD" button to add a row.   |
| Excess rows can be removed by pressin                          | ig the "X" button.                                     |  |

Poehlein 2



| Patent?  | Pending?       | Issued?   | Licensed?     | Royalties?     | Licensee?          | Comments                     |       |
|--|----------------|-----------|---------------|----------------|--------------------|------------------------------|-------|
| Augmentation of immune response<br>to cancer vaccine (US 20090317407<br>A1)                  |                | <b>✓</b>  |               |                |                    |                              |       |
| Section 5. Relationsh  | ips not cove   | ered abo  | ove           |                |                    |                              |       |
| Are there other relationships or potentially influencing, what yo                            |                |           |               | eive to have   | influenced, or tha | at give the appearance of    |       |
| Yes, the following relationsl  | •              |           |               | •              | •                  | st                           |       |
| At the time of manuscript acce<br>On occasion, journals may ask a                            |                |           |               |                |                    |                              | nents |
| Section 6. Disclosure S  | Statement      |           |               |                |                    |                              |       |
| Based on the above disclosures below.  | , this form wi | ll automa | ntically gene | erate a disclo | sure statement, v  | which will appear in the box | (     |
| Dr. Poehlein reports personal for submitted work. In addition, Divaccine (US 20090317407A1). |                |           |               |                | •                  |                              |       |

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Poehlein 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



| Section 1. Identifying Informa  |   |                         |                                     | ı       |
|---|---|-------------------------|-------------------------------------|---------|
| Identifying Informa   | ation   |                         |                                     |         |
| Given Name (First Name)  David  | 2. Surname (Last Name)<br>Quinn   |                         | 3. Date<br>27-October-2016          |         |
| 4. Are you the corresponding author?  | ☐ Yes ✓ No  | Corresponding Author    | r's Name                            |         |
| 5. Manuscript Title<br>Pembrolizumab as Second-Line Therapy   | for Advanced Urothelial   | Carcinoma               |                                     |         |
| 6. Manuscript Identifying Number (if you kno  | ow it)  | _                       |                                     |         |
|   |   |                         |                                     |         |
| Section 2. The Work Under Co  | nsideration for Public  | cation                  |                                     |         |
| Did you or your institution <b>at any time</b> received any aspect of the submitted work (including be statistical analysis, etc.)?  Are there any relevant conflicts of interest   | out not limited to grants, da   |                         |                                     | c.) for |
| Section 3. Relevant financial a   | ctivities outside the s   | submitted work.         |                                     |         |
| Place a check in the appropriate boxes in of compensation) with entities as describ clicking the "Add +" box. You should report there any relevant conflicts of interest lf yes, please fill out the appropriate information. | eed in the instructions. Use ort relationships that were transfer Yes  Mo | se one line for each en | tity; add as many lines as you need | d by    |
| Name of Entity  | Grant? Personal Nor   | n-Financial other?      | Comments                            |         |
| Merck   |   |                         | Advisory board                      |         |
| Bristol-Myers Squibb  |   |                         | Advisory board                      |         |
| Genentech   |   |                         | Advisory board                      |         |
| AstraZeneca   |   |                         | Advisory board                      |         |
| Pfizer  |   |                         | Advisory board                      |         |
| Novartis  |   |                         | Advisory board                      |         |
| Astellas  |   |                         | Advisory board                      |         |
| Peloton Therapeutics  |   |                         | Advisory board                      | 1       |



| Name of Entity  | Grant?      | Personal Fees? | Non-Financial Support? | Other?     | Comments                           |  |  |  |
|---|-------------|----------------|------------------------|------------|------------------------------------|--|--|--|
| Dendreon Corp.  |             | <b>√</b>       |                        |            | Advisory board                     |  |  |  |
| Exelexis  |             | <b>✓</b>       |                        |            | Advisory board                     |  |  |  |
| Bayer   |             | <b>✓</b>       |                        |            | Advisory board                     |  |  |  |
| Pirimal Life Sciences   |             | <b>✓</b>       |                        |            | Advisory board                     |  |  |  |
| Sanofi  |             | <b>✓</b>       |                        |            | Advisory board                     |  |  |  |
| Section 4.  Intellectual Property Patents & Copyrights  Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes   No   |             |                |                        |            |                                    |  |  |  |
| Section 5. Relationships not o  | overed      | above          |                        |            |                                    |  |  |  |
| Are there other relationships or activities potentially influencing, what you wrote i   |             |                |                        | nfluence   | d, or that give the appearance of  |  |  |  |
| Yes, the following relationships/cond   | ditions/cir | cumstance      | es are present (exp    | olain belc | w):                                |  |  |  |
| No other relationships/conditions/ci  | rcumstan    | ces that pre   | esent a potential o    | conflict o | finterest                          |  |  |  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. |             |                |                        |            |                                    |  |  |  |
| Section 6. Disclosure Stateme   | nt          |                |                        |            |                                    |  |  |  |
| Based on the above disclosures, this form below.  | n will auto | omatically (   | generate a disclos     | sure state | ment, which will appear in the box |  |  |  |
| Dr. Quinn reports personal fees from Me<br>Peloton Therapeutics, Dendreon Corp., I  |             | •              | •                      |            |                                    |  |  |  |



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Sternberg 1



**Identifying Information** 

Section 1.

# **ICMJE Form for Disclosure of Potential Conflicts of Interest**

| 1. Given Name (First Name)<br>Cora N.  | 2. Surname (Last Nam<br>Sternberg  | e)                      | 3. Date<br>31-October-2016             |            |
|--|------------------------------------|-------------------------|--|------------|
| 4. Are you the corresponding author?   | ☐ Yes    ✓ No                      | Correspond<br>Joaquim E | ding Author's Name<br>Bellmunt         |            |
| 5. Manuscript Title<br>Pembrolizumab as Second-Line Thera  | apy for Advanced Uroth             | elial Carcinoma         |  |            |
| 6. Manuscript ldentifying Number (if you 16-13683  | know it)                           |                         |  |            |
| Section 2. The Work Under  | Consideration for Pu               | phlication              |  |            |
| Did you or your institution at any time re any aspect of the submitted work (includi statistical analysis, etc.)?  Are there any relevant conflicts of interesting the submitted work of the submitted | ceive payment or services to grant | from a third party      |  |            |
|  |                                    |                         |  |            |
| Section 3. Relevant financia   | al activities outside t            | he submitted            | work.                                  |            |
| Place a check in the appropriate boxe of compensation) with entities as des clicking the "Add +" box. You should it  | cribed in the instruction          | s. Use one line fo      | or each entity; add as many lines as y | ou need by |
| Are there any relevant conflicts of inte   |                                    | lo                      |  |            |
| If yes, please fill out the appropriate in   | nformation below.                  |                         |  |            |
| Name of Entity   | Grant? Personal Fees?              | Non-Financial Support?  | Other? Comments                        |            |
| OncoGeneX  |                                    |                         | Honoraria                              |            |
| Eli Lilly  | <b>✓</b>                           |                         | Honoraria and Research Fund            | ding       |
| Janssen  | <b>✓</b>                           |                         | Research Funding                       |            |
| Merck  |                                    |                         | Honoraria                              |            |
| Bristol-Myers Squibb   |                                    |                         | Honoraria                              |            |
| AstraZeneca  | <b>✓</b>                           |                         | Research Funding                       |            |
| Roche/Genentech  | <b>✓</b>                           |                         | Research Funding                       |            |

Sternberg 2



| Southern 4   |
|--|
| Section 4. Intellectual Property Patents & Copyrights  |
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume  |
| Section 5. Relationships not covered above   |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  |
| Yes, the following relationships/conditions/circumstances are present (explain below):   |
| No other relationships/conditions/circumstances that present a potential conflict of interest  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement  |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.  |
| Dr. Sternberg reports grant support from Janssen, AstraZeneca, and Roche/Genentech, grant support and personal fees from Eli Lilly, and personal fees from OncoGeneX, Merck, and Bristol-Myers Squibb outside the submitted work.    |

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Sternberg 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Vaughn 1



| Section 1. Identifying Info   | ormation   |   |
|---|--|---|
| Given Name (First Name)  David  | 2. Surname (Last Name)<br>Vaughn   | 3. Date<br>27-October-2016  |
| 4. Are you the corresponding author?  | ☐ Yes ✓ No   | Corresponding Author's Name<br>Joaquim Bellmunt   |
| 5. Manuscript Title<br>Pembrolizumab as Second-Line The   | rapy for Advanced Urothelial   | Carcinoma   |
| 6. Manuscript Identifying Number (if yo   | u know it)   |   |
|   |  |   |
| Section 2. The Work Unde  | r Consideration for Public   | cation  |
| any aspect of the submitted work (inclu<br>statistical analysis, etc.)?<br>Are there any relevant conflicts of in | ding but not limited to grants, da<br>terest?  | a third party (government, commercial, private foundation, etc.) for ita monitoring board, study design, manuscript preparation, we more than one entity press the "ADD" button to add a row. |
| Name of Institution/Company   | Grant  | n-Financial other? Comments   |
| Merck   | <b>V</b>   | Clinical trial research funding   |
|   |  |   |
| Section 3. Relevant finance   | ial activities outside the s   | ubmitted work.  |
| of compensation) with entities as de  | escribed in the instructions. Used report relationships that were terest?    Yes    No | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.              |
| Name of Entity  | Grant  | n-Financial other? Comments   |
| Astellas  |  | DSMB  |

Vaughn 2



| Section 4. Intellectual Property Patents & Copyrights   |
|---|
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo   |
| Section 5. Relationships not covered above  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?   |
| Yes, the following relationships/conditions/circumstances are present (explain below):  |
| No other relationships/conditions/circumstances that present a potential conflict of interest   |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statement On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement   |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.   |
| Dr. Vaughn reports grant support from Merck during the conduct of the study, and personal fees from Astellas outside the submitted work.  |

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Vaughn 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Vogelzang 1



| Section 1.   | Identifying Inform  | nation   |  |   |
|--|---|--|--|---|
| 1. Given Name (Fi<br>Nicholas  | rst Name)   | 2. Surname (Last Name<br>Vogelzang                                 | )  | 3. Date<br>19-November-2016   |
| 4. Are you the cor   | responding author?  | ☐ Yes ✓ No   | Corresponding A                                    |   |
| 5. Manuscript Title<br>Pembrolizumab   |   | y for Advanced Urothel   | ial Carcinoma                                      |   |
| 6. Manuscript Idei<br>16-13683   | ntifying Number (if you kn                                      | now it)  |  |   |
|  | ı   |  |  |   |
| Section 2.   | The Work Under Co   | onsideration for Pul   | olication  |   |
| any aspect of the s<br>statistical analysis,<br>Are there any rel<br>If yes, please fill o | ubmitted work (including<br>etc.)?<br>evant conflicts of intere | sut not limited to grants, est? Yes No<br>prmation below. If you h | data monitoring boar                               | rnment, commercial, private foundation, etc.) for d, study design, manuscript preparation, entity press the "ADD" button to add a row.      |
| Name of Institut   | ion/Company   | Grant? Personal Fees?  | Ion-Financial Support?                             | er? Comments  |
| Merck  |   |  |  | Advisory board meeting  |
|  | l   |  |  |   |
| Section 3.   | Relevant financial  | activities outside th  | e submitted work                                   | c.  |
| of compensation<br>clicking the "Adc<br>Are there any rel                                  | ) with entities as descri                                       | bed in the instructions.<br>port relationships that v              | Use one line for eac<br>vere <b>present during</b> | nancial relationships (regardless of amount<br>th entity; add as many lines as you need by<br><b>g the 36 months prior to publication</b> . |
| Section 4.   | Intellectual Proper   | ty Patents & Copy  | rights   |   |
| Do you have any  | patents, whether plan   | ned, pending or issued,  | broadly relevant to                                | the work? Yes No  |

Vogelzang 2



| Section 5.                 |   |
|----------------------------|---|
| Section 5.                 | Relationships not covered above   |
|                            | relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?  |
| Yes, the follo             | wing relationships/conditions/circumstances are present (explain below):  |
| No other rela              | tionships/conditions/circumstances that present a potential conflict of interest  |
|                            | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>rnals may ask authors to disclose further information about reported relationships. |
| Section 6.                 | Disclosure Statement  |
| Based on the abo<br>below. | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box   |
| Dr. Vogelzang re           | eports personal fees from Merck during the conduct of the study.  |

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Vogelzang 3